Technology
Nov. 9, 2026
Where's the human? Bio-AI and the law's missing person
Every legal gate in the life sciences assumes a person stands behind it: an inventor who conceives, a clinician who reviews, a physician who decides. Artificial intelligence is quietly walking that person out of the room.
This summer, a drug whose biological target was nominated by one AI system and whose chemical structure was drafted by another entered Phase III. Insilico Medicine's rentosertib, an oral TNIK inhibitor for idiopathic pulmonary fibrosis, is being tested in a trial planned to enroll up to 320 patients at 47 sites in China over 52 weeks. If it completes Phase III, it would be the first drug originated largely by generative AI to complete that stage of clinical testing.
The verbs i...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$895, but save $100 when you subscribe today… Just $795 for the first year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In